Bharat Biotech seeks trial for intranasal COVID-19 vaccine booster – ET HealthWorld

Indian vaccine maker Bharat Biotech said on Monday it has submitted an application to the country’s drug regulator to conduct a late-stage trial for a booster dose of its intranasal COVID-19 vaccine. Indian COVID-19 vaccine makers are lobbying the government to authorise boosters as supplies have far outstripped demand, but the health ministry said there is no immediate plan to approve boosters and the priority remains complete vaccination of eligible adults. “We have submitted phase 3 clinical trial application to DCGI (Drugs Controller General of India),” a Bharat Biotech spokesperson…

Read More

UK Begins Trial Of Multivariant COVID-19 Vaccine Booster

A phase one trial of a multivariant COVID-19 vaccine booster drug has got underway among participants aged over 60 in the UK. The trial, involving GRT-R910, has been launched by US pharmaceutical company Gritstone in collaboration with the University of Manchester and Manchester University NHS Foundation Trust. It will explore the potential of the drug to boost the immune response of first-generation COVID-19 vaccines to a wide array of variants of Sars-Cov-2, which cause COVID-19. “We think GRT-R910 as a booster vaccination will elicit strong, durable, and broad immune responses,…

Read More

COVID-19: Pfizer, Moderna seen reaping billions of dollars from vaccine booster market – ET HealthWorld

REUTERS/Agustin Marcarian Drugmakers Pfizer Inc, BioNTech and Moderna Inc are expected to reap billions of dollars from COVID-19 booster shots in a market that could rival the $6 billion in annual sales for flu vaccines for years to come, analysts and healthcare investors say. For several months, the companies have said they expect that fully inoculated people will need an extra dose of their vaccines to maintain protection over time and to fend off new coronavirus variants. Now a growing list of governments, including Chile, Germany and Israel, have decided…

Read More